Immuron Limited Is A Biopharmaceutical Company Based In Melbourneaustraliafocused On Developing Targeted Polyclonal Antibody Therapies For Infectious Diseasesparticularly Gastrointestinal Disordersfounded In 1994The Company Is Publicly Listed On The Asx And Nasdaqimmuron Operates Through Two Main Segmentsresearch & Development And Hyperimmune Productsutilizing Proprietary Technology To Create Dairy Derived Polyclonal Antibodies The Company Offers Products Such As Travelana An Oral Immunotherapy For Reducing The Risk Of Travelersaediarrheaand Protectyna A Colostrum Based Immune Supplement For Digestive Healthimmuron Is Also Advancing Several Pipeline Candidates Aimed At Treating Recurrent Infectionsincluding Imm 124E For Campylobacteriosis And Imm 529 For Clostridioides Difficile Infectionstheir Innovative Approach Addresses Antimicrobial Resistancecontributing To Global Health Solutionsimmuron Collaborates With Various Partnersincluding The U Sdepartment Of Defenseto Enhance Its Impact In The Healthcare Sector
